Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Decoy Therapeutics Inc.FLKS · Entity 937 | Chief Operating Officer | January 18, 2017 | January 20, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Decoy Therapeutics Inc.
Report date January 18, 2017 · Filed January 20, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.58 · Expires 2027-01-18 | Direct | 77,000 |
Reported balance
After 2017-01-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-18 · Grant · Acquired 77,000 · Balance 77,000 F1: The stock option will vest in 48 successive equal monthly installments measured from January 18, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option will vest in 48 successive equal monthly installments measured from January 18, 2017.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 18, 2017 Filed Jan 20, 2017 14:03 UTC | Decoy Therapeutics Inc. FLKS · Entity 937 | GrantStock Option (right to buy) · Derivative | 77,000 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0001615219-17-000008 · wf-form4_148492098003213.xml · derivative · entry 1 Lindemann Katharine · CIK 0001652493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,000 Underlying: Common Stock · 77,000 shares Expires 2027-01-18 F1 · derivative.exercise_date: The stock option will vest in 48 successive equal monthly installments measured from January 18, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.